Australia markets open in 4 hours 46 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.7300+0.1200 (+7.45%)
As of 03:13PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 83.34M
Enterprise value -106.43M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.37
Enterprise value/revenue N/A
Enterprise value/EBITDA 1.35

Trading information

Stock price history

Beta (5Y monthly) 1.64
52-week change 3-63.07%
S&P500 52-week change 320.07%
52-week high 39.7200
52-week low 31.1750
50-day moving average 31.6858
200-day moving average 33.6282

Share statistics

Avg vol (3-month) 3583.02k
Avg vol (10-day) 3542.49k
Shares outstanding 551.44M
Implied shares outstanding 651.44M
Float 841.01M
% held by insiders 12.95%
% held by institutions 199.47%
Shares short (28 Mar 2024) 42.6M
Short ratio (28 Mar 2024) 43.73
Short % of float (28 Mar 2024) 45.94%
Short % of shares outstanding (28 Mar 2024) 45.06%
Shares short (prior month 29 Feb 2024) 41.98M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.17%
Return on equity (ttm)-29.24%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -78.88M
Net income avi to common (ttm)-68.96M
Diluted EPS (ttm)-1.4400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)203.06M
Total cash per share (mrq)3.95
Total debt (mrq)13.29M
Total debt/equity (mrq)5.89%
Current ratio (mrq)14.78
Book value per share (mrq)4.39

Cash flow statement

Operating cash flow (ttm)-55.66M
Levered free cash flow (ttm)-32.94M